WuXi XDC and LegoChem Biosciences Signed Memorandum of Understanding for the Development and Manufacturing of Antibody-drug Conjugates
WUXI, China and DAEJEON, South Korea, June 10, 2021 /PRNewswire/ -- WuXi XDC ("XDC"), a global CDMO company dedicated to end-to-end bioconjugates services, and LegoChem Biosciences (141080KS,"LCB"), today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnershi...
2021-06-10 08:30
4714
CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate
* CStone to acquire exclusive rights for development and commercialization outsideSouth Korea for LCB71, an ROR1 antibody drug conjugate * Agreement adds to CStone's pipeline a potential first-in-class/best-in-class drug candidate with monotherapy and combination applications for a range of c...
2020-10-29 07:15
3648
